

DAFTAR PUSTAKA

- Andrieu, C., Duseti, N. J., Giusiano, S., Bastide, C., Gleave, M., Tarangercharpin, C., & Bourrellys, C. (2012). TP53INP1 Overexpression in Prostate Cancer Correlates With Poor Prognostic Factors and Is Predictive of Biological Cancer Relapse. *Wiley Online Library*. <http://doi.org/10.1002/pros.21412>
- Ashtari, S., Pourhoseingholi, M. A., Sharifian, A., Zali, M. R., Ashtari, S., & Pourhoseingholi, M. A. (2015). Hepatocellular carcinoma in Asia: Prevention strategy and planning. *World Journal of Hepatology*. <http://doi.org/10.4254/wjh.v7.i12.1708>
- Bala, S., Tilahun, Y., Taha, O., Alao, H., Kodys, K., Catalano, D., & Szabo, G. (2012). Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. *Journal of Translational Medicine*. <http://doi.org/10.1186/1479-5876-10-151>
- Bialecki, E. S., & Bisceglie, A. (2005). Diagnosis of hepatocellular carcinoma, *HPB Journal*. <http://doi.org/10.1080/13651820410024049>
- Bomben, R., Gobessi, S., Dal Bo, M., Volinia, S., Marconi, D., Tissino, E., & Gattei, V. (2012). The miR-17-92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes, *Nature*. <http://doi.org/10.1038/leu.2012.44>
- Cano, C. E., Gommeaux, J., Pietri, S., Culcasi, M., Barelier, S., Vasseur, S., & Carrier, A. (2009). Tumor Protein 53 – Induced Nuclear Protein 1 Is a Major Mediator of p53 Antioxidant Function, *American Association for Cancer Research*. <http://doi.org/10.1158/0008-5472>.
- Charan, J., & Biswas, T. (2013). How to Calculate Sample Size for Different Study Designs in Medical Research. *Indian Journal of Psychological Medicine*. <http://doi.org/10.4103/0253-7176.116232>
- Dhanasekaran, R., Bandoh, S., & Roberts, L. R. (2016). Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000 Faculty*. <http://doi.org/10.12688/f1000research.6946.1>
- Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009). miR-155 gene: A typical multifunctional microRNA. *Biochimica et Biophysica Acta*. <http://doi.org/10.1016/j.bbadis.2009.02.013>
- Forner, A., Gilibert, M., Bruix, J., & Raoul, J. (2014). Treatment of intermediate-stage hepatocellular carcinoma. *Nature*. <http://doi.org/10.1038/nrclinonc.2014.122>
- Fu, X., Wen, H., Jing, L., Yang, Y., Wang, W., Liang, X., & Yao, Y. (2017). MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K / Akt pathway. *Japanese Cancer Association*. <http://doi.org/10.1111/cas.13177> 104

- Galun, D., Basaric, D., Zuvela, M., Bulajic, P., Bogdanovic, A., Bidzic, N., & Milicevic, M. (2015). Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. *World Journal of Hepatology*. <http://doi.org/10.4254/wjh.v7.i20.2274>
- Gironella, M., Seux, M., Xie, M.-J., Cano, C., Tomasini, R., Gommeaux, J., & Dusetti, N. J. (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. *The National Academy of Sciences of the USA*. <http://doi.org/10.1073/pnas.0703942104>
- Gori, M., Arciello, M., & Balsano, C. (2014). MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools during the Transition from Steatosis to Hepatocarcinoma. *Biomed Research International*. <http://doi.org/10.1091/cncr.26788>
- Guan, C., Yang, F., He, X., Li, T., Yang, Q., He, H., & Xu, M. (2015). Clinical significance of microRNA-155 expression in hepatocellular carcinoma. *Oncology Letters*. <http://doi.org/10.3892/ol.2015.4048>
- Han, Z., Chen, H.-Y., Fan, J.-W., Wu, J.-Y., Tang, H.-M., & Peng, Z.-H. (2012). Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. *Journal of Cancer Research and Clinical Oncology*. <http://doi.org/10.1007/s00432-011-1076-z>
- Hanahan, D., & Weinberg, R. A. (2011). Review Hallmarks of Cancer : The Next Generation. *Cell*. <http://doi.org/10.1016/j.cell.2011.02.013>
- Hannafon, B. N., & Ding, W. (2013). Intercellular Communication by ExosomeDerived microRNAs in Cancer. *International Journal of Molecular Science*. <http://doi.org/10.3390/ijms140714240>
- Hershko, T., Chaussepied, M., Oren, M., & Ginsberg, D. (2005). Novel link between E2F and p53 : proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. *Nature*. <http://doi.org/10.1038/sj.cdd.4401575>
- Higgs, G., & Slack, F. (2013). The multiple roles of microRNA-155 in oncogenesis. *Journal of Clinical Bioinformatics*. <http://doi.org/10.1186/2043-9113-3-17>
- Hiotis, P., Rahbari, N., Villanueva, A., Klegar, E., Luan, W., Wang, Q., & Yee, H. T. (2012). Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. *BioMed Central: Gastroenterology*. <http://doi.org/10.1186/1471-230X-12-64>
- Hung, C. H., Chiu, Y. C., Chen, C. H., & Hu, T. H. (2014). MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression, and therapeutic target. *Biomed Research International*. <http://doi.org/10.1155/2014/486407>
- Ivan, M., & Huang, X. (2014). Tumor Microenvironment and Cellular Stress. *PubMed Central*. <http://doi.org/10.1007/978-1-4614-5915-6>

- Kementrian Kesehatan RI Pusat Data dan Informasi Kesehatan. (2015). Stop Kanker. *Infodatin-Kanker*.
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., & Tajiri, H. (2015). Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World Journal of Hepatology*. <http://doi.org/10.4254/wjh.v7.i3.406>
- Li, J., Fang, L., Yu, W., & Wang, Y. (2015). MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif. *Oncology Letters*. <http://doi.org/10.3892/ol.2015.2973>
- Liu, F., Kong, X., Lv, L., & Gao, J. (2015). MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. *FEBS Letters*. <http://doi.org/10.1016/j.febslet.2015.01.009>
- Lowe, S. W., & Lin, a W. (2000). Apoptosis in cancer. *Carcinogenesis*. <http://doi.org/10.1093/carcin/21.3.485>
- Ma, S., Tang, K. H., Chan, Y. P., Lee, T. K., Kwan, P. S., Castilho, A., & Guan, X. Y. (2010). MiR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. *Cell: Stem Cell*. <http://doi.org/10.1016/j.stem.2010.11.010>
- Matsuda, K., Yoshida, K., Taya, Y., Nakamura, K., Nakamura, Y., & Arakawa, H. (2002). p53AIP1 Regulates the Mitochondrial Apoptotic Pathway 1. *Science And Technology*. <http://doi.org/10.1099/cncr.26.900>
- Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosovaagadjanyan, E. L., & Tewari, M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. *PNAS*. <http://doi.org/10.10912/cncr.27821>
- Nakajima, T., Yasui, K., Zen, K., Inagaki, Y., Fujii, H., Minami, M., & Arii, S. (2008). Activation of B-Myb by E2F1 in hepatocellular carcinoma. *Hepatology research*. <http://doi.org/10.1111/j.1872-034X.2008.00324.x>
- Nowak, J., Bontemps, C., Carrier, A., Tomasini, R., Iovanna, J. L., Dusetti, N. J., & Dagorn, J. (2005). TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. *Nature*. <http://doi.org/10.1038/sj.onc.1208951>
- Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., & Sarin, S. K. (2010). Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatology International*. <http://doi.org/10.1007/s12072-010-9165-7>
- Pan, H., Liao, S., Lai, W., Lu, H., Hsiao, K., Pan, H., & Hsiao, K. (2017). Overexpression but Lack of Mutation and Methylation of p73 in Hepatocellular Carcinoma Overexpression but Lack of Mutation and Methylation of p73 in Hepatocellular Carcinoma. *Acta Oncologica*. <http://doi.org/10.1080/02841860214968>

- Porta, C., Amici, M. De, Quaglini, S., Paglino, C., Tagliani, F., Boncimino, A., & Corazza, G. R. (2008). Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. *Annals of Oncology*. <http://doi.org/10.1093/annonc/mdm448>
- Saadi, H., Seillier, M., Carrier, A., Saadi, H., Seillier, M., & Carrier, A. (2016). The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. *Elsevier*. <http://doi.org/10.1016/j.biochi.2015.07>.
- Seillier, M., Peugot, S., Dusetti, N. J., & Carrier, A. (2012). Antioxidant Role of p53 and of Its Target TP53INP1. Shahbazi, J., Lock, R., & Liu, T. (2013). Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis. *Frontiers in Genetics*. <http://doi.org/10.3389/fgene.2013.00080>
- Su, C., Hou, Z., Zhang, C., Tian, Z., & Zhang, J. (2011). Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. *Virology Journal*. <http://doi.org/10.1186/1743-422X-8-354>
- Sun, J., Lu, H., Wang, X., & Jin, H. (2013). MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. *Scientific World Journal*. <http://doi.org/10.1155/2013/924206>
- Tang, B., Lei, B., Qi, G., Liang, X., Tang, F., Yuan, S., & Wang, Z. (2016). MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. *Journal of Experimental & Clinical Cancer Research*. <http://doi.org/10.1186/s13046-016-0371-6>
- Tu, T., Budzinska, M. A., Maczurek, A. E., Cheng, R., Di Bartolomeo, A., Warner, F. J., & Shackel, N. A. (2014). Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. *International Journal of Molecular Sciences*. <http://doi.org/10.3390/ijms15069422>
- Wang, B., Ma, W., Sulaiman, A., Noer, S., Sumoharjo, S., Sumarsidi, D., & Mishiro, S. (2002). Demographic, Clinical, and Virological Characteristics of Hepatocellular Carcinoma in Asia: Survey of 414 Patients From Four Countries. *Journal of Medical Virology*. <http://doi.org/10.1002/jmv.10087>
- Witwer, K. W. (2015). Circulating MicroRNA Biomarker Studies: Pitfalls and Potential Solutions. *Clinical Chemistry*. <http://doi.org/10.1373/clinchem.2014.221341>
- Xie, Q., Chen, X., Lu, F., Zhang, T., Hao, M., & Wang, Y. (2012). Aberrant Expression of MicroRNA 155 May Accelerate Cell Proliferation by Targeting Sex-Determining Region Y Box 6 in Hepatocellular Carcinoma. *Wiley Online Library*. <http://doi.org/10.1002/cncr.26566>

- Yano, Y., Utsumi, T., Lusida, M. I., & Hayashi, Y. (2015). Hepatitis B virus infection in Indonesia. *World Journal of Gastroenterology*. <http://doi.org/10.3748/wjg.v21.i38.10714>
- Yeung, M. L., Yasunaga, J., Bennasser, Y., Dusetti, N., Ahmad, N., Matsuoka, M., & Jeang, K. (2008). Roles for microRNA, miR-93 and miR-130b, and TP53INP1 tumor suppressor in cell growth dysregulation by HTLV-1. *National Institutes of Health*. <http://doi.org/10.1158/0008-5472>.
- Zeng, H., Fang, C., Nam, S., Cai, Q., & Long, X. (2014). The clinicopathological significance of microRNA-155 in breast cancer: a meta-analysis. *Biomed Research International*. <http://doi.org/10.1155/2014/724209>
- Zhang, J., Cheng, C., Yuan, X., He, J., Pan, Q., & Sun, F. (2014). microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma. *International Journal of Clinical Experiment of Pathology*. <http://doi.org/10.8910/cncr.29866.x>
- Zhang, L., Wang, W., Li, X., He, S., Yao, J., Wang, X., & Sun, X. (2016). MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. *International Journal of Oncology*. <http://doi.org/10.3892/ijo.2016.3465>
- Zhu, R. X., Seto, W., Lai, C., & Yuen, M. (2016). Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *PubMed Central*. <http://doi.org/10.1102/cncr.267421>